Raltegravir (MK-0518)

Name: Raltegravir (MK-0518)
Brand: Selleck Chemicals
SKU: S2005
Rating: 5 (44 reviews)

For research use only.

Catalog No.S2005

44 publications

Raltegravir (MK-0518) Chemical Structure

CAS No. 518048-05-0

Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM in cell-free assays, respectively. It shows greater than 1000-fold selectivity for HIV-1 IN over several related Mg2+-dependent enzyme such as HCV polymerase, HIV reverse transcriptase, HIV RNaseH and human α-, β-, γ-polymerases.

Selleck's Raltegravir (MK-0518) has been cited by 44 publications

Cancer Cell, 2019, 36(4):385-401

PubMed: 31564637 ( click the link to review the publication )

Nature, 2016, 530(7590):358-61

PubMed: 26887496 ( click the link to review the publication )

Int J Nanomedicine, 2021, 16:1189-1206

PubMed: 33623382 ( click the link to review the publication )

EBioMedicine, 2021, 65:103241

PubMed: 33647768 ( click the link to review the publication )

J Immunol, 2020, 204(5):1242-1254

PubMed: 31988180 ( click the link to review the publication )

J Virol, 2020, JVI.01386-20

PubMed: 33298546 ( click the link to review the publication )

J Virol, 2020, JVI.01247-20

PubMed: 33239456 ( click the link to review the publication )

Blood Adv, 2020, 12;4(9):1845-1858

PubMed: 32369565 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

J Virol, 2019, 93(9)

PubMed: 30760577 ( click the link to review the publication )

JCI Insight, 2019, 4(12)

PubMed: 31217351 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3450

PubMed: 30150664 ( click the link to review the publication )

Elife, 2018, 7e36245

PubMed: 29941091 ( click the link to review the publication )

mBio, 2018, 9(6)

PubMed: 30401776 ( click the link to review the publication )

PLoS Pathog, 2018,

PubMed: 29470552 ( click the link to review the publication )

J Infect Dis, 2018, 218(11):1773-1776

PubMed: 30010985 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Virol J, 2018, 15(1):152

PubMed: 30285810 ( click the link to review the publication )

JCI Insight, 2018, 3(19)

PubMed: 30282829 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(3):392-404

PubMed: 30173955 ( click the link to review the publication )

J Clin Invest, 2017, 127(12):4352-4364

PubMed: 29083319 ( click the link to review the publication )

Cell Rep, 2017, 18(5):1324-1334

PubMed: 28147284 ( click the link to review the publication )

Cell Death Dis, 2017, 8(6):e2852

PubMed: 28569776 ( click the link to review the publication )

J Virol, 2017, 91(24)

PubMed: 29021396 ( click the link to review the publication )
Antimicrob Agents Chemother, 2017, 61(8)

PubMed: 28533248 ( click the link to review the publication )

Wellcome Open Res, 2017, 2:87

PubMed: 29062917 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(14):6896-906

PubMed: 27369381 ( click the link to review the publication )

Front Microbiol, 2016, 7:1944

PubMed: 27990142 ( click the link to review the publication )

Bioorg Med Chem, 2016, 24(11):2410-22

PubMed: 27117260 ( click the link to review the publication )

Sci Signal, 2015, 8(399):ra104

PubMed: 26486173 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 10.1128/AAC.00114-15

PubMed: 25779572 ( click the link to review the publication )

Virology, 2015, 484:364-76

PubMed: 26186575 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(6):3168-76

PubMed: 24663015 ( click the link to review the publication )

Antimicrob Agents Chemother., 2014, 58(8):4431-42

PubMed: 24867983 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105617

PubMed: 25144636 ( click the link to review the publication )

PLoS Pathog, 2013, 9(1):e1003125

PubMed: 23349632 ( click the link to review the publication )

J Virol, 2013, 87(17):9768-79

PubMed: 23824795 ( click the link to review the publication )

Retrovirology, 2013, 10:144

PubMed: 24261564 ( click the link to review the publication )

PLoS One, 2013, 8(11):e81489

PubMed: 24282600 ( click the link to review the publication )

Sci Rep, 2013, 3:2103

PubMed: 23812503 ( click the link to review the publication )

Blood, 2012, 120(17):3488-90

PubMed: 22955925 ( click the link to review the publication )

J Virol, 2012, 86(17):9337-50

PubMed: 22718820 ( click the link to review the publication )

Virus Res, 2012, 171(1):121-8

PubMed: 23201205 ( click the link to review the publication )

Vet Microbiol, 2011, 152(1-2):165-8

PubMed: 21570781 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Integrase Inhibitors

Biological Activity

Description

Features

The 1st approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor.

Targets

Integrase (S217Q PFV) ^[1] (Cell-free assay)	Integrase (WT PFV) ^[1] (Cell-free assay)
40 nM	90 nM

In vitro

PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC50 of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC50 of 200 nM, indicating a ~twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. S217Q PFV IN is as sensitive to Raltegravir as the WT enzyme. ^[1] Raltegravir is metabolized by glucuronidation, not hepatically. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31?0 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEMx174 cells, with an IC95 of 6 nM. Raltegravir metabolism occurs primarily through glucuronidation. Drugs that are strong inducers of the glucuronidation enzyme, UGT1A1, significantly reduce Raltegravir concentrations and should not be used. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. Raltegravir does not induce CYP3A4 RNA expression or CYP3A4-dependent testosterone 6-β-hydroxylase activity. ^[2] Raltegravir cellular permeativity is reduced in the presence of magnesium and calcium. ^[3] Raltegravir and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs efficiently block viral replication. ^[4] In acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEMx174, SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC90 in the low nanomolar range. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
MT4	M{XQWmFvfGm4aYLhcEBie3OjeR?=			MUHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25uIFXDOVAhRSByLkCwNVQh\|ryPLh?=	MkXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NEG3NlYoRjF6NUSxO\|I3RC:jPh?=
MT-4	NUHpW5pTSW62aY\pdoFtKGG\|c3H5			M4ri[WFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSB\|QjDpcoZm[3SnZDDpckBpfW2jbjDNWE01KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36sJGVEPTBiPTCwMlAxOThizszNMi=>	NITjSFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEG2NFUzOSd-MUixOlA2OjF:L3G+
MT-4	M330SWFvfGm4aYLhcEBie3OjeR?=			MlHRRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgeoV{cWO3bHHyJJN1d22jdHn0bZMhfmm{dYOgS{1xe2W3ZH;0fZBm\CCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW\|IHnu[oVkfGWmIHnuJIh2dWGwIF3UMVQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjygSWM2OCB;IECuNFAzKM7:TT6=	MnjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThzNkC1NlEoRjF6MU[wOVIyRC:jPh?=
MT2	NWG4cGRiSW62aY\pdoFtKGG\|c3H5		M{foPVMhfG9iNDDkZZl{	NUD2VoNmSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDOUFQuOyCrbn\lZ5Rm\CCrbjDoeY1idiCPVEKgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyC2bzC0JIRigXNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwJF0hOC5yMEKg{txONg>?	MmixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzJyOEGwNVAoRjN{MEixNFExRC:jPh?=
MT-2	MkHBRY51cX[rcnHsJIF{e2G7			NXuwdVVNSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXC1{IHPlcIx{KGK7IIT3c{Bnd2ymIHTpcJV1cW:wIH3leIhw\CCrbjDwdoV{\W6lZTDv[kAyOCViRlLTMEBGSzVyIE2gNE4xODNizszNMi=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFyNECxNEc,OTlzMESwNVA9N2F-
MT2	MUDBcpRqfmm{YXygZZN{[Xl?		MWK1JIRigXN?	NUjxSGVXSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDJiY3XscJMh[W[2ZYKgOUBl[Xm\|IHL5JINp\W2rbIXtbY5me2OnbnPlJIlvKHC{ZYPlcoNmKG:oIH\leIFtKGKxdnnu[UB{\XK3bTygSWM2OCB;IECuNFA1KM7:TT6=	MknVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{OEWzPFkoRjF7Mki1N\|g6RC:jPh?=
HOS	NHrKc4lCdnSrdnnyZYwh[XO\|YYm=			M1TTemFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiaHHyZo9zcW6pIIfpcIQufHmyZTDpcpRm\3Kjc3WgbY5n\WO2ZXSgbY4hcHWvYX6gTG9UKGOnbHzzMEBGSzVyIE2gNE4xODRizszNMi=>	NF\Semw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS5N\|A3Pid-MkG0PVMxPjZ:L3G+
HOS	NWnvUmJwSW62aY\pdoFtKGG\|c3H5		NI\n[GU{KGi{cx?=	MUXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDD3bYxlNXS7cHWgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKGmwZnXjeIVlKGmwIFjPV{Bk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEOgbJJ{KG[xbHzve4VlKGK7II\pdoFtKGmwZnXjeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxKD1iMD6wNFQh\|ryPLh?=	NVvFN5BJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|E5OTZpPkK0OFcyQDF4PD;hQi=>
MT2	NFPDVXJCdnSrdnnyZYwh[XO\|YYm=		NFXtNWU2KGSjeYO=	MXrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnuJG1VOiClZXzsd{Bi\nSncjC1JIRigXNuIFXDOVAhRSByLkCwOkDPxE1w	MnvKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{MEezPVgoRjF6MkC3N\|k5RC:jPh?=
MT-4	NVXrXW1bSW62aY\pdoFtKGG\|c3H5			MlHHRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXKDFiUlnOJIhiemKxcnnu[{BqdnSnZ4Lhd4Uh\2WwZTDpcoZm[3SnZDDpckBOXC12IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDifUBOXFRiYYPzZZktKEWFNUCgQUAxNjByNjFOwG0v	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN5OEexN{c,OTh\|N{i3NVM9N2F-
MT4	NIHpTJJCdnSrdnnyZYwh[XO\|YYm=			NWOyR3FYSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFAvODB4IN88UU4>	NHPEUFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyQCd-MkS5NFA4OTh:L3G+
MT4	NH;IeIRCdnSrdnnyZYwh[XO\|YYm=			M4nJOmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXi1zIEPCJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCycn;0[YN1cW:wIHHnZYlve3RidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBjgSCPVGSgZZN{[XluIFXDOVAhRSByLkCwOkDPxE1w	NXTwXHQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PVM{PjBpPkK0O\|k{OzZyPD;hQi=>
MT4	MnLORY51cX[rcnHsJIF{e2G7			NYnieGNMSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIEPCJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW\|IHnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RuIFXDOVAhRSByLkCwOlEh\|ryPLh?=	NEfxR4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES3PVIxPid-MkC0O\|kzODZ:L3G+
MT4	Mm\OSpVv[3Srb36gZZN{[Xl?		MkX2NUBpeg>?	M4\KbmlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFjJWlEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IIXzbY5oKGOnbHzzJJBz\S2rbnP1ZoF1\WRid3n0bEBkd22yb4Xu[EBnd3JiMTDodkBu\WG\|dYLl[EA1KGSjeYOgdI9{fCC4aYLhcEBqdm[nY4Tpc44h[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNFYzKM7:TT6=	M{O2OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[zNVM2Lz5{Mkm2N\|E{PTxxYU6=
MT4	M2[0S2FvfGm4aYLhcEBie3OjeR?=			MXrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZidnnyeZMucW6mdXPl[EBkgXSxcHH0bI9o\W6rY3n0fUBjgSCPVGSgZZN{[XluIFXDOVAhRSByLkCwOlQh\|ryPLh?=	M3i0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NES3OlIyLz5zOUS0O\|YzOTxxYU6=
MT-4	NUj0U3pCSW62aY\pdoFtKGG\|c3H5			Ml;sRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXKDFiTly0MlMhcGG{Yn;ybY5oKGmwdHXndoF{\SCON{TNJI12fGGwdDDpcoZm[3SnZDDpckBpfW2jbjDNWE01KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCkeTDNWHQh[XO\|YYmsJGVEPTBiPTCwMlAxPyEQvF2u	M4f5O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{e4O\|E{Lz5zOEO3PFcyOzxxYU6=
MT4	M4jqXGFvfGm4aYLhcEBie3OjeR?=			M4T4dmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCkeTDNWHQh[XO\|YYmsJGVEPTBiPTCwMlAxPzhizszNMi=>	M{LEd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUWxNFk2Lz5{OEm1NVA6PTxxYU6=
MT-4	NXXLcWJQSW62aY\pdoFtKGG\|c3H5			MnXhRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB\|QjDpcoZm[3SnZDDpckBpfW2jbjDNWE01KGOnbHzzJIJ6KHS5bzDmc4xlKGSrbIX0bY9vKG2ndHjv[EBqdiCycnXz[Y5k\SCxZjCxNEUhTkKVLDDFR\|UxKD1iMD6wNFgh\|ryPLh?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFyNECxNEc,OTlzMESwNVA9N2F-
MT-4	M{nkXWFvfGm4aYLhcEBie3OjeR?=			NEDKPJRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZiMTDOUFQvOyCrboTl[5Jie2ViU{KzNG4hdXW2YX70JIlv\mWldHXkJIlvKGi3bXHuJG1VNTRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFAvODB7IN88UU4>	MlvkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|N{i3NVMoRjF6M{e4O\|E{RC:jPh?=
MT4	M2\xcWFvfGm4aYLhcEBie3OjeR?=		M4PnVlQ5KHSxIEeyJIhzew>?	M{nJV2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHX4dJJme3OrbnegS2ZRKGmwY4XiZZRm\CCob4KgOFghfG9iN{KgbJJ{KGmwIHHid4Vv[2Vib3[gOVAmKG6xcn3hcEBpfW2jbjDz[ZJ2dSCkeTDteYx1cXCuZTDyc5Vv\CC4aYLhcEBz\XCuaXPheIlwdiCtaX7leIlkeyCjc4PhfUwhUVBiPTCwMlAxQSEQvF2u	M2r4c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m3PVY2Lz5{NkO5O\|k3PTxxYU6=
FL-4	NG\4XFZCdnSrdnnyZYwh[XO\|YYm=			M3LSSWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGZmdGmwZTDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KGmwZnXjeIVlKGmwIHPheEBHVC12IHPlcIx{KGG\|c3Xzd4VlKGG\|II\pdoFtKFKQQTDwdo9lfWO2aX;uJIJ6KFKWLYHQR3ItKEWFNUCgQUAxNjByOUm4JO69VS5?	NGTwRWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixN\|c{Oid-MkS4NVM4OzJ:L3G+
MT-4	M{\Cc2FvfGm4aYLhcEBie3OjeR?=			NGG5SINCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZiMTDSTW4hcGG{Yn;ybY5oKGmwdHXndoF{\SCpZX7lJIlv\mWldHXkJIlvKE2WLUSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIJ6KE2WVDDhd5NigSCjZoTldkAzOCCyYYPzZYdmeyC\|ZXzlZ5Rm\CCrbjDwdoV{\W6lZTDv[kBkd22yb4Xu[EwhTUN3MDC9JFAvODFizszNMi=>	MoLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|N{i3NVMoRjF6M{e4O\|E{RC:jPh?=
HeLa	M{\leWFvfGm4aYLhcEBie3OjeR?=		MVu0PEBpenN?	NX3GNFZYSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYMTDs[Y51cX[rcnHsJJBienSrY3zld{Bqdm[nY4Tl[EBqdiCqdX3hckBJ\UyjIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK\|IHL5JJNx\WO2cn;mcJVwem:vZYTyfUwhUUN3MDC9JFAvODFizszNMi=>	M{TQb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEW4N\|AxLz5{Mki1PFMxODxxYU6=
cat FL-4	NUH2OolMSW62aY\pdoFtKGG\|c3H5		MV63JIRigXN?	MUHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDG[YxqdmViaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{Bqdm[nY4Tl[EBqdiClYYSgSmwuPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIILldIxq[2G2aX;uJIFnfGW{IEeg[IF6eyCkeTDxeYFvfGm2YYTpeoUhWlRvUFPSJIFv[Wy7c3nzMEBGSzVyIE2gNE4xOSEQvF2u	MmO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEK4OFkoRjJ3N{CyPFQ6RC:jPh?=
cat FL-4	NFLNTJhCdnSrdnnyZYwh[XO\|YYm=		NGnLbXU4KGSjeYO=	MnvkRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgSmlXKGmwZnXjeIVlKGmwIHPheEBHVC12IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckB3cXKjbDDSUmEhdGW4ZXygcYVie3W{ZXSgZYZ1\XJiNzDkZZl{KGK7IIHSWE1RS1JiYX7hcJl{cXNuIFXDOVAhRSByLkCxJO69VS5?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTN7NUWxNEc,OzF\|OUW1NVA9N2F-
MT4	M3;vfWFvfGm4aYLhcEBie3OjeR?=			MmK3RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOiCUT1SgN2IhcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{YXytbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDifUBOXFRiYYPzZZktKEWFNUCgQUAxNjBzMTFOwG0v	NFz6TXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1NVA6PSd-Mki5OVExQTV:L3G+
MT4	M3fGemFvfGm4aYLhcEBie3OjeR?=			MkfGRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKDOEIHnu[oVkfGWmIHnuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCycn;0[YN1cW:wIHHnZYlve3RidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBu\WG\|dYLl[EA2KGSjeYOgdI9{fCCrbn\lZ5Rqd25iYomgUXRVKGG\|c3H5MEBGSzVyIE2gNE4xOTF5IN88UU4>	NGPCPHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NFQ3Oid-Mkm5OFA1PjJ:L3G+
MT4	M1nXXmFvfGm4aYLhcEBie3OjeR?=			NUjXdVJISW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuLXnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RiaX6gbJVu[W5iTWS0JINmdGy\|LDDFR\|UxKD1iMD6wNVMh\|ryPLh?=	NEXFNWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESxO\|M1Oid-MUi0NVc{PDJ:L3G+
MT4	MYfBcpRqfmm{YXygZZN{[Xl?			MkLhRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0MEBGSzVyIE2gNE4xOTNizszNMi=>	NYDid3A6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2N\|A4PjVpPkKwOlMxPzZ3PD;hQi=>
MT4	NEXSWJZCdnSrdnnyZYwh[XO\|YYm=			MUDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[nliTWTUJIF{e2G7LDDFR\|UxKD1iMD6wNVMh\|ryPLh?=	MnPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{Mke1OVAoRjJzMkK3OVUxRC:jPh?=
BL21(DE3)	M{jnTGZ2dmO2aX;uJIF{e2G7		NUPzfZVTOSCqch?=	NI\JXYxKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhKXi1zIHnueIVoemG\|ZTDzeIFv\CC2cnHud4ZmeiCjY4Tpeol1gSCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyMESHMzmgZ4VtdHNidYPpcochOzKSLXzhZoVt\WRiRF7BJJN2[nO2cnH0[UBi\nSncjCxJIhzKGK7IHTlcpNqfG:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjBzMzFOwG0v	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR3MUe3NUc,OjZ2NUG3O\|E9N2F-
MT-4	M{n2RWFvfGm4aYLhcEBie3OjeR?=			NXj1WZNsSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYIEGgUmw1NjNiaX70[Ydz[XOnIFW5NnEhdXW2YX70JIlv\mWldHXkJIlvKGi3bXHuJG1VNTRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFAvODF3IN88UU4>	NEKxUG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO3PFcyOyd-MUizO\|g4OTN:L3G+
MT4	MmrURY51cX[rcnHsJIF{e2G7		NIHre2E2KGSjeYO=	NYLOSm5QSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMhcW6ldXLheIVlKG[xcjC1JIRigXNiYomgUXRVKGG\|c3H5MEBGSzVyIE2gNE4xOTVizszNMi=>	NXrtVo1mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GzNlQ2PjJpPkOxN\|I1PTZ{PD;hQi=>
MT2	M2L3dGFvfGm4aYLhcEBie3OjeR?=			MVTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYhcW5iTWSyJINmdGy\|IHnuJJBz\XOnbnPlJI9nKDN3IH3nM41NKGi3bXHuJJNmenWvIHHsZpVucW5uIFXDOVAhRSByLkCxOkDPxE1w	M{n2W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkC3N\|k5Lz5zOEKwO\|M6QDxxYU6=
MT-4	NW[1TnlJSW62aY\pdoFtKGG\|c3H5		MkO0OUBl[Xm\|	NXK5UYNRSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRk9NSUliaX7m[YN1\WRiaX6gbJVu[W5iTWStOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5QhdWWjc4Xy[YQhe3W{dnn2ZYwh[W[2ZYKgOUBl[Xm\|IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFAvODF4IN88UU4>	MoGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkS5NVkoRjJ2MUK0PVE6RC:jPh?=
HeLa-CD4-LTR-beta-gal	NGnEdXhCdnSrdnnyZYwh[XO\|YYm=		M4DmO\|Eh\GG7	M1;COGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXi1zIEPCJIlv\mWldHXkJIlvKGi3bXHuJGhmVGFvQ1S0MWxVWi2kZYThMYdidCClZXzsd{Bi\nSncjCxJIRigSCkeTDzdIVkfHKxc3PvdIlkKGGwYXz5d4l{NCCHQ{WwJF0hOC5yMU[g{txONg>?	MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkmyOVYoRjJ3NkK5NlU3RC:jPh?=
MT-2	M3j4XWFvfGm4aYLhcEBie3OjeR?=			M2PsbmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQuOiClZXzsd{BjgSC2d3:g[o9t\CCmaXz1eIlwdiCvZYToc4QhcW5icILld4Vv[2Vib3[gNVAmKE[EUzygTHNCKGGwZDDhcJBp[TFvQVfQMEBGSzVyIE2gNE4xOThizszNMi=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFyNECxNEc,OTlzMESwNVA9N2F-
MT4	M4rtVmFvfGm4aYLhcEBie3OjeR?=			NYn3TJlCSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdiCqdX3hckBOXDRiY3XscJMhcW5icILld4Vv[2Vib3[gNVAmKGinYYStZYN1cX[jdHXkJIZmfGGuIHLveolv\SC\|ZYL1cUwhUUN7NTC9JFAvODF7IN88UU4>	NVXldYw2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OlM4PTFpPkG4O\|Y{PzVzPD;hQi=>
MT2	NHmzco5CdnSrdnnyZYwh[XO\|YYm=		MWi1JIRigXN?	MU\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UNkBk\WyuczDh[pRmeiB3IHThfZMh[nliY3jlcYltfW2rbnXzZ4Vv[2ViaX6gdJJme2WwY3Wgc4YhcHWvYX6gd4VzfW1iYXzieY1qdixiRVO1NEA:KDBwMEKg{txONg>?	NGT1SJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK4OVM5QSd-MUmyPFU{QDl:L3G+
MT4	M2TCbmFvfGm4aYLhcEBie3OjeR?=		M33lXVUh\GG7cx?=	NGDCPYdCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZ{IGLPSEBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMhcW6ldXLheIVlKG[xcjC1JIRigXNiYomgUXRVKGG\|c3H5MEBGSzVyIE2gNE4xOiEQvF2u	M2r4NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzM{K0OVYzLz5\|MUOyOFU3OjxxYU6=
TZM-b1	NX7sUXdySW62aY\pdoFtKGG\|c3H5		NG\V[ZoyKGi{	NFqzOpFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZvMTDOUFQvOyCrbn\lZ5Rm\CCrbjDoeY1idiCWWl2tZlEh[2WubIOgdJJmfHKnYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSC4aYLhcEBqdm[nY4Tpc44hdWWjc4Xy[YQh[W[2ZYKgNkBl[Xm\|IHL5JGNRWkdiYYPzZZktKEmFNUCgQUAxNjB{MTFOwG0v	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRyOEKyOEc,Ojh2MEiyNlQ9N2F-
CEM-SS	M1fL[2FvfGm4aYLhcEBie3OjeR?=		M1fyWVYh\GG7cx?=	NX;aVFBtSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBETU1vU2OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgZYZ1\XJiNjDkZZl{KGK7IF3UV{Bie3OjeTygSWM2OCB;IECuNFI{KM7:TT6=	M17xdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkizNlYyLz5{N{K4N\|I3OTxxYU6=
HeLa	M3HKdmFvfGm4aYLhcEBie3OjeR?=		NYO0NG1pOyCmYYnz	M4jMOGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gTIVN[SClZXzsd{BmgHC{ZYPzbY5oKEOGND3MWHIu[mW2YT3nZYwh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDy[ZBtcWOjdHnvckBi\nSncjCzJIRigXNiYomgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvODJ\|NjFOwG0v	NXPoVpZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFQzPzBpPkK0Olg1OjdyPD;hQi=>
HeLa-CD4-LTR-beta-gal	NGXHbodCdnSrdnnyZYwh[XO\|YYm=			MnjWRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXNTFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gTIVN[S2FREStUHRTNWKndHGt[4FtKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZpkhW3CnY4TyZW1igCCJRV3JUmkuYFNicHzheIUhemWjZHXyJIFv[Wy7c3nzMEBGSzVyIE2gNE4xOjN4IN88UU4>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MUm2NEc,OjV7NkG5OlA9N2F-
HeLa	MmPKRY51cX[rcnHsJIF{e2G7		M1\NcFIh\GG7cx?=	MkH2RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB\|QjDpcoZm[3SnZDDpckBpfW2jbjDI[WxiKGOnbHzzJIV5eHKnc4PpcochS0R2IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25iYX\0[ZIhOiCmYYnzJIJ6KGKndHGt[4Ft[WO2b4Pp[IF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxKD1iMD6wNlQh\|ryPLh?=	MknWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkS5NVkoRjJ2MUK0PVE6RC:jPh?=
MT-4	NVW5[mFlSW62aY\pdoFtKGG\|c3H5			NV7WfpVpSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYIEGgVmlPKEiLVjCxJHJKViCqYYLic5JqdmdiaX70[Ydz[XOnIHflcoUhcW6oZXP0[YQhcW5iTWStOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[nliTWTUJIF{e2G7IHHmeIVzKDRyIIDhd5Ni\2W\|IIPlcIVkfGWmIHnuJJBz\XOnbnPlJI9nKGOxbYDveY5lNCCHQ{WwJF0hOC5yMkWg{txONg>?	MlvRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|N{i3NVMoRjF6M{e4O\|E{RC:jPh?=
TZM-bl	M4[4S2FvfGm4aYLhcEBie3OjeR?=		MlrqOFghcHK\|	Mn7vRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKGmwZnXjeIVlKGmwIHj1cYFvKFScTT3icEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKHKncHzpZ4F1cW:wIHHmeIVzKDR6IHjyd{BjgSCrbo\ldpRm\CCvaXPyc5Nkd3CrYzDhcoFtgXOrczygSWM2OCB;IECuNFI2KM7:TT6=	NXvnN2NnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVQ4PjJpPkKyNVU1PzZ{PD;hQi=>
MT4	NEjWfGJHfW6ldHnvckBie3OjeR?=		Ml\ONUBpeg>?	MVvJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCKSW[xJFNDKGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyC3c3nu[{Bk\WyuczDwdoUucW6ldXLheIVlKHerdHigZ49ueG:3bnSg[o9zKDFiaIKgcYVie3W{ZXSgOEBl[Xm\|IIDvd5Qhfmm{YXygbY5n\WO2aX;uJIlvKHC{ZYPlcoNmKG:oIEKwJI1oN22uIFjTRUBjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCyPUDPxE1w	M2PRNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[zNVM2Lz5{Mkm2N\|E{PTxxYU6=
P4R5 MAGI	NFfqWVFCdnSrdnnyZYwh[XO\|YYm=		NIL6UWkzPCCqcoO=	MYfBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGmwZnXjeIVlKGmwIFPEOE9EYEOUND;DR3I2KGW6cILld5NqdmdiaIXtZY4hWDSUNTDNRWdKKGOnbHzzJJBz\WmwY4XiZZRm\CC5aYToJINmdGy\|IH\vdkAzPCCqcoOg[o9tdG:5ZXSgZpkhfmm{YXygbY5n\WO2aX;uJI1m[XO3cnXkJIFnfGW{IES4JIhzeyCkeTDi[ZRiNWejbHHjeI9{cWSjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvODNizszNMi=>	NXiycm5XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|E6PzZpPkOwNFMyQTd4PD;hQi=>
P4R5	NU\4WW46SW62aY\pdoFtKGG\|c3H5		NIXuN3IzPCCqcoO=	M{OxVmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiaX7m[YN1\WRiaX6gR2Q1N0O[Q2K0M2NEWjViZYjwdoV{e2mwZzDoeY1idiCSNGK1JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25icILlbY5kfWKjdHXkJJdqfGhiY3XscJMh\m:{IEK0JIhzeyCob3zsc5dm\CCkeTD2bZJidCCrbn\lZ5Rqd25ibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJIJ6KGKndHGt[4Ft[WO2b4Pp[IF{\SC{ZYDvdpRmeiCpZX7lJIF{eyxiRVO1NEA:KDBwMEOg{txONg>?	NYHzUGZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NlUzPzlpPkK4OVI2Ojd7PD;hQi=>
P4R5	MlPnRY51cX[rcnHsJIF{e2G7		NUe3Z4hSOjRiaILz	Mm\LRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCrbn\lZ5Rm\CCrbjDoeY1idiCSNGK1JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC4aYLhcEBqdm[nY4Tpc44heHKnaX7jeYJifGWmIIfpeIgh[2WubIOg[o9zKDJ2IHjyd{Bnd2yub4fl[EBjgSC4aYLhcEBqdm[nY4Tpc44hdWWjc4Xy[YQh[W[2ZYKgOFghcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCkYYPl[EBj\XSjLXfhcIFkfG:\|aXThd4UhemWyb4L0[ZIh\2WwZTDiZZNm\CCPQVfJJIF{NCCHQ{WwJF0hOC5yMzFOwG0v	NHm1TIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUCzNVA3Oid-MkmwN\|ExPjJ:L3G+
P4R5	M4TSemFvfGm4aYLhcEBie3OjeR?=		MUGyOEBpenN?	MkP5RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXNTFiaX7m[YN1\WRiaX6gbJVu[W5iUETSOUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5idnnyZYwhemWybHnjZZRqd25icILlbY5kfWKjdHXkJIZweiB{NDDodpMh\m:ubH;3[YQh[nlidnnyZYwhcW6oZXP0bY9vKGGwZDDt[YF{fXKnZDDh[pRmeiB2ODDodpMh[nliTVHHTUBie3OjeTygSWM2OCB;IECuNFMh\|ryPLh?=	NUfrUI9vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C3N\|k5OjJpPkOwO\|M6QDJ{PD;hQi=>
P4R5	NIHrNYxCdnSrdnnyZYwh[XO\|YYm=		MonYNlQhcHK\|	NXL2eXMxSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDpcoZm[3SnZDDpckBpfW2jbjDQOHI2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjD2bZJ2eyC{ZYDsbYNifGmxbjDwdoVqdmO3YnH0[YQhf2m2aDDj[YxteyCob4KgNlQhcHK\|IH\vcIxwf2WmIHL5JJZqemGuIHnu[oVkfGmxbjDmc5IhPDhiaILzJIJ6KDRvbXX0bJltfW2kZXzsbYZmenmuZ3HsZYN1d3OrZHWtZoF{\WRiTVHHTUBie3OjeTygSWM2OCB;IECuNFMh\|ryPLh?=	MkXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd{OEOyOlEoRjJ5MkizNlYyRC:jPh?=
MT4	M1eyUGFvfGm4aYLhcEBie3OjeR?=			NXO4TFgxSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdiCqdX3hckBOXDRiY3XscJMhcW5icILld4Vv[2Vib3[gOVAmKG6xcn3hcEBpfW2jbjDz[ZJ2dSxiSVO5OUA:KDBwMEOxJO69VS5?	Mn\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh5NkO3OVEoRjF6N{[zO\|UyRC:jPh?=
MT4	M4jrW2FvfGm4aYLhcEBie3OjeR?=		NWPh[W4zPDhidH:gO\|IhcHK\|	M{jPV2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHX4dJJme3OrbnegS2ZRKGmwY4XiZZRm\CCob4KgOFghfG9iN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJFUxLSCwb4LtZYwhcHWvYX6gd4VzfW1iYomgcZVtfGmybHWgdo92dmRidnnyZYwhemWybHnjZZRqd25ia3nu[ZRq[3NiYYPzZZktKEmSIE2gNE4xPTNizszNMi=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7N{m2OUc,OjZ\|OUe5OlU9N2F-
BL21(DE3)	NYXqWZVlTnWwY4Tpc44h[XO\|YYm=		MYSxJIhz	MVjJcohq[mm2aX;uJI9nKEyHRFfGM5A4PS2mZYDlcoRmdnRiZoXscEBt\W6pdHigTGlXNTFiaX70[Ydz[XOnIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFqRFWzLUBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEGgbJIh\nW{dHjldkBqdmO3YnH0[YQh\m:{IEmwJI1qdnNid3n0bEBjcW:2aX6tcIFj\WynZDDkc45weiCGTlGgZY5lKHSjcnfleEBFVkFiYomgTHRTTiCjc4PhfUwhUUN3MDC9JFAvODV6IN88UU4>	Mmf2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF2NEK2PFQoRjNzNESyOlg1RC:jPh?=
MT-4	M4PSfWFvfGm4aYLhcEBie3OjeR?=			M{\mcWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXiBzIGLJUkBJUVZiMTDSTW4hcGG{Yn;ybY5oKGmwdHXndoF{\SCpZX7lJIlv\mWldHXkJIlvKE2WLUSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIJ6KE2WVDDhd5NigSCjZoTldkA3OCCyYYPzZYdmeyC\|ZXzlZ5Rm\CCrbjDwdoV{\W6lZTDv[kBkd22yb4Xu[EwhTUN3MDC9JFAvODZ6IN88UU4>	NWDzbpNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|g4OTNpPkG4N\|c5PzF\|PD;hQi=>
HeLaT4	NIO1[oZCdnSrdnnyZYwh[XO\|YYm=			M3PYNGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJNqdmeuZT3yc5Vv\CCKSW[xJG5NYC6OdYitVkBp[XKkb4LpcochcW6jY4TpeoF1cW6pIH31eIF1cW:wczDpckBmdnZuII\wdkBidmRiY3HydolmeyCoaYLl[ox6KGy3Y3nm[ZJie2ViZ3Xu[UBqdiCybHHj[UBw\iCwZX[gZZN{\XO\|ZXSgZZMhdGW4ZXygc4YhOiCvaX7zJI1i\26ndHnjJI5idm:yYYL0bYFtey2vZXTheIVlKGmwZnXjeIlwdiCrbjDoeY1idiCKZVzhWFQh[2WubIOgeJJm[XSnZDDmc5IhOSxiRVO5NUA:KDBwMEezJO69VS5?	M2fzfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzME[wNVA5Lz5{MUC2NFExQDxxYU6=
HeLa-T4	M3\SSmFvfGm4aYLhcEBie3OjeR?=		MnrLOFghcHK\|	MofmRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sgd4lv\2ynLYLveY5lKEiLVkGgUmxZNky3eD3SJIhiemKxcnnu[{BqdmGldHn2ZZRqdmdibYX0ZZRqd26\|IHnuJIVvfixidoDyJIFv\CClYYLybYV{KG[rcnXmcJkhdHWlaX\ldoF{\SCpZX7lJIlvKHCuYXPlJI9nKG6nZjDpcoZm[3SnZDDpckBpfW2jbjDI[WxiNVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHz1Z4ln\XKjc3WgZYN1cX[rdImgZYZ1\XJiNEigbJJ{KGK7IHX4c4dmdm:3czDSWEBie3OjeTygSWM2OCB;IECuNFc4KM7:TT6=	NUfxNJBIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwOlAyODhpPkKxNFYxOTB6PD;hQi=>
TZM-bl	Ml3lRY51cX[rcnHsJIF{e2G7		NHjDWWs1QCCqcoO=	M1nrSGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXi1zIHnu[oVkfGWmIHnuJIh2dWGwIGTaUU1jdCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIILldIxq[2G2aX;uJIZweiB2ODDodpMh[nliYoLp[4h1NUeubzDseYNq\mW{YYPlJIF{e2G7LDDFR\|UxKD1iMD6xOUDPxE1w	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR6N{mxN{c,OjZ2OEe5NVM9N2F-
HOS	M1vHcmFvfGm4aYLhcEBie3OjeR?=		M{XmeVMhcHK\|	NV\kc5ZFSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIHjhdoJwemmwZzDpcpRm\3Kjc3WgUlE2PUhibYX0ZY51KGmwZnXjeIVlKGmwIFjPV{Bk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEOgbJJ{KG[xbHzve4VlKGK7II\pdoFtKGmwZnXjeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxKD1iMD6xOVQh\|ryPLh?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUixOkc,OjR2N{G4NVY9N2F-
TZM-bl	NGLrR2xCdnSrdnnyZYwh[XO\|YYm=			NHm0RZNCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIF7MOE4{KGmwZnXjeIVlKGmwIHj1cYFvKFScTT3icEBk\WyuczDt[YF{fXKnZDD1dJRwKDJ2IHjyd{BjgSCkcnnnbJQhT2yxLXz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvOTZizszNMi=>	NVuzZ3VzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1OVc3ODlpPkOxOVU4PjB7PD;hQi=>
HOS	NISxOJZCdnSrdnnyZYwh[XO\|YYm=		MVKzJIhzew>?	M3\qbWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCqYYLic5JqdmdiaX70[Ydz[XOnIGmxOFNTKG23dHHueEBqdm[nY4Tl[EBqdiCKT2OgZ4VtdHNicILlbY5kfWKjdHXkJIZweiB\|IHjyd{Bnd2yub4fl[EBjgSC4aYLhcEBqdm[nY4Tpc44hdWWjc4Xy[YQh[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwMU[yJO69VS5?	NWDp[plXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|E5OTZpPkK0OFcyQDF4PD;hQi=>
TZM-bl	M4\ReGFvfGm4aYLhcEBie3OjeR?=		Mn36NUBpeg>?	NYfMb\|BzSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDOUFQvOyCrbn\lZ5Rm\CCrbjDoeY1idiCWWl2tZowh[2WubIOg[ZhxemW\|c3nu[{BEYEOUND30do9xcWNiaX7jeYJifGWmIH\vdkAyKGi{IIDybY9zKHSxIHnu[oVkfGmxbjDt[YF{fXKnZDDh[pRmeiB2ODDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE42KM7:TT6=	NXrpeVZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVExPDJpPkK0NlkyODR{PD;hQi=>
TZM-bl	MnH6RY51cX[rcnHsJIF{e2G7		NFLOO\|QyKGi{	MmL4RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTESuN{Bqdm[nY4Tl[EBqdiCqdX3hckBVYk1vYnygZ4VtdHNiZYjwdoV{e2mwZzDDXGNTPC22cn;wbYMhcW6ldXLheIVlKG[xcjCxJIhzKHC{aX;yJJRwKGmwZnXjeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD61NFEyQSEQvF2u	MlXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUGwOFIoRjJ2MkmxNFQzRC:jPh?=
HeLa-T4	Mme5RY51cX[rcnHsJIF{e2G7		M{XQSVQ5KGi{cx?=	M1rmXWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJNqdmeuZT3yc5Vv\CCKSW[xJG5NYC6OdYitVkBp[XKkb4LpcochcW6jY4TpeoF1cW6pIH31eIF1cW:wczDpckBmdnZuII\wdkBidmRiY3HydolmeyCoaYLl[ox6KGy3Y3nm[ZJie2ViZ3Xu[UBqdiCybHHj[UBw\iCwZX[gbY5n\WO2ZXSgbY4hcHWvYX6gTIVN[S2WNDDj[YxteyCjc4Pld5Nm\CCjczDseYNq\mW{YYPlJIFkfGm4aYT5JIFnfGW{IES4JIhzeyCkeTDlfI9o\W6xdYOgVnQh[XO\|YYmsJGVEQTViPTCwMlgyKM7:TT6=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB4MEGwPEc,OjFyNkCxNFg9N2F-
HOS	MlLHRY51cX[rcnHsJIF{e2G7		MXqzJIhzew>?	NXLNd2pVSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIHjhdoJwemmwZzDpcpRm\3Kjc3WgS\|E1OFNxUUG0PGgh\G:3YnzlJI12fGGwdDDpcoZm[3SnZDDpckBJV1NiY3XscJMheHKnaX7jeYJifGWmIH\vdkA{KGi{czDmc4xtd3enZDDifUB3cXKjbDDpcoZm[3Srb36gcYVie3W{ZXSgZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFEvQSEQvF2u	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUixOkc,OjR2N{G4NVY9N2F-
MT2	NIfCSXRCdnSrdnnyZYwh[XO\|YYm=		M2XOVlMhfG9iNDDkZZl{	MoCxRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTEStN{Bp[XKkb4LpcochTzF2MGOvVVE1QEhibYX0ZY51KGmwZnXjeIVlKGmwIHj1cYFvKE2WMjDj[YxteyCvZXHzeZJm\CCjZoTldkA{KHSxIESg[IF6eyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUCgQUAzNjR{IN88UU4>	NVLwUplZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{KwPFExOTBpPkOyNFgyODFyPD;hQi=>
HeLaT4	NH;Ve4dCdnSrdnnyZYwh[XO\|YYm=		Mlj2NlQhcHK\|	NFTMXJBCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB{cW6pbHWtdo92dmRiSFnWNUBPVFhwTIX4MXIhcGG{Yn;ybY5oKGmwYXP0bZZifGmwZzDteZRifGmxboOgbY4h\W64LDD2dJIh[W6mIHPhdpJq\XNiZnny[YZtgSCudXPp[oVz[XOnIHflcoUhcW5icHzhZ4Uhd2ZibnXmJIF{e2W\|c3XkJIF{KGyndnXsJI9nKGmwZnXjeIlwdiC3c3nu[{BpfW2jbjDI[WxiXDRiY3XscJMheHKndILlZZRm\CCob4KgNlQhcHK\|IH\vcIxwf2WmIHL5JIV5eG:\|ZXSgeI8hfmluIFXDOVAhRSB2Lk[g{txONg>?	NIPafXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC2NFExQCd-MkGwOlAyODh:L3G+
MT4	NYGwe2g4S3m2b4TvfIlkcXS7IHHzd4F6		NGLkd3c2KGSjeYO=	M3\TOWN6fG:2b4jpZ4l1gSCrbjDtc4NsNWmwZnXjeIVlKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliaX7jeYJifGWmIH\vdkA2KGSjeYOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hPi53MTFOwG0v	NVvER4hbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GzNlQ2PjJpPkOxN\|I1PTZ{PD;hQi=>
CHO	Mn\jSpVv[3Srb36gZZN{[Xl?			M3nDWGlvcGmkaYTpc44hd2Zic3zve{Bl\WyjeXXkJIlvf2G{ZDDy[YN1cW[7aX7nJJBwfGG\|c3n1cUBkfXK{ZX70JEhKc3NrIHnuJGNpcW6nc3WgTIFue3SncjDPeoFzgSBqQ1jPLUBk\WyuczDlfJBz\XO\|aX7nJIhMfkyTVEGvbI1qdktibXXhd5Vz\WRidYPpcochUW:wV3;yb5MhWXWjdITyc{BifXSxbXH0[YQheGG2Y3igZ4xidXBicHzheIZwem1uIFnDOVAhRSB{NT6xNVg6KM7:TT6=	NUfwNVFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPFc4PTNpPkK1NFg4PzV\|PD;hQi=>
U373-MAGI	NU[4W4hSSW62aY\pdoFtKGG\|c3H5	MknYOVAhd3JiMUCwJI5O	MXG3NkBpenN?	MmjtRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDnZYchdGW4ZXygZZQhPTBib4KgNVAxKG6PIH3lZZN2emWmIHH0JFczKGi{czDwc5N1KGmwZnXjeIlwdiCkeTDxVGNTKG2ndHjv[C=>	M2jZVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO\|I3ODxxYU6=
U373-MAGI	NXGxO2l6SW62aY\pdoFtKGG\|c3H5	M1LwcFUxKG:{IEGwNEBvVQ>?	M33wOFczKGi{cx?=	M2rNUWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHZUXi2JIIDz[ZVld3S7cHXkJGhKXi1zIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKFV\|N{OtUWFIUSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gWVUu\2GpIHzleoVtKGG2IEWwJI9zKDFyMDDuUUBu\WG\|dYLl[EBifCB5MjDodpMheG:\|dDDpcoZm[3Srb36gZpkheVCFUjDt[ZRpd2R?	NHHZfpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|I3OCd-MkexNVczPjB:L3G+
MT2	NXn0XFhXSW62aY\pdoFtKGG\|c3H5	M1rY[\|EhfU1?	NYnHd\|hVOzBiaILz	MX\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDD3bYxlNXS7cHWgTGlXOSCQTEStN{Bqdm[nY4Tl[EBqdm[nY4Tl[EBqdiCqdX3hckBOXDJiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGhKXjFiaX70[Ydz[XSnZDDEUmEh[XRiMTD1UUBidmRibXXhd5Vz\WRiYX\0[ZIhOzBiaILzJJBwe3RiaX7m[YN1cW:wIHL5JGFtfS2OVGKgVGNTKHC{b4TvZ49tKGKjc3XkJI1mfGixZB?=	MkHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7OU[3PFAoRjNyOUm2O\|gxRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CHOP / ATF-4 / XBP-1 / Lamin B; PubMed: 24625618 PLoS One Mouse J774A.1 cells were treated with different concentrations of raltegravir (0, 5, 15, 25 or 50 µM) in the absence or presence of ritonavir (RITV, 25 µM) or thapsigargin (TG, 100 nM), a known ER stress inducer, for 4 h, and the nuclear proteins were iso䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뾠Ղ䐺痖暼瘿뾠Ղᾰƌ 뾠ՂÐ㺣痖뾠Ղ𢡄	24625618

In vivo

Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate shows an undetectable viral load following Raltegravir monotherapy. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse PFV integration assay: For quantitative strand transfer assays, donor DNA substrate is formed by annealing HPLC grade oligonucleotides 5′-GACTCACTATAGGGCACGCGTCAAAATTCCATGACA and 5′-ATTGTCATG GAATTTTGACGCGTGCCCTATAGTGAGTC. Reactions (40 μL) contains 0.75 μM PFV IN, 0.75 μM donor DNA, 4 nM (300 ng) supercoiled pGEM9-Zf(−) target DNA, 125 mM NaCl, 5 mM MgSO₄, 4 μM ZnCl₂, 10 mM DTT, 0.8% (vol/vol) DMSO, and 25 mM BisTris propane–HCl, pH 7.45. Raltegravir is added at indicated concentrations. Reactions are initiated by addition of 2 μL PFV IN diluted in 150 mM NaCl, 2 mM DTT, and 10 mM Tris-HCl, pH 7.4, and stopped after 1 hour at 37 °C by addition of 25 mM EDTA and 0.5% (wt/vol) SDS. Reaction products, deproteinized by digestion with 20 μg proteinase K for 30 minutes at 37 °C followed by ethanol precipitation, are separated in 1.5% agarose gels and visualized by staining with ethidium bromide. Integration products are quantified by quantitative real-time PCR, using Platinum SYBR Green qPCR SuperMix and three primers: 5′-CTACTTACTCTAGCTTCCCGGCAAC, 5′-TTCGCCAGTTAATAGTTTGCGCAAC, and 5′-GACTCACTATAGGGCACGCGT. PCR reactions (20 μL) contained 0.5 μM of each primer and 1 μL diluted integration reaction product. Following a 5-min denaturation step at 95 °C, 35 cycles are carried out in a CFX96 PCR instrument, using 10 seconds denaturation at 95 °C, 30 seconds annealing at 56 °C and 1 minutes extension at 68 °C. Standard curves are generated using serial dilutions of WT PFV IN reaction in the absence of INSTI.
Cell Research: ^[5]	- Collapse Cell lines: Human MT-4 cells Concentrations: 0.0001-1 μM Incubation Time: 5 days Method: Human MT-4 cells are infected for 2 hours with the SIVmac251, HIV-1 (IIIB) and HIV-2 (CDC 77618) stocks at a multiplicity of infection of, approximately, 0.1. Cells are then washed three times in phosphate buffered saline, and suspended at 5 × 10⁵/mL in fresh culture medium (to primary cells 50 units/mL of IL-2 are added) in 96-well plates, in the presence or absence of a range of triplicate raltegravir concentrations (0.0001 μM -1 μM). Untreated infected and mock-infected controls are prepared too, in order to allow comparison of the data derived from the different treatments. Viral cytopathogeniciy in MT-4 cells is quantitated by the methyl tetrazolium (MTT) method (MT-4/MTT assay) when extensive cell death in control virus-infected cell cultures is detectable microscopically as lack of capacity to re-cluster. The capability of MT-4 cells to form clusters after infection. Briefly, clusters are disrupted by pipetting; and, after 2 hours of incubation at 37 °C, the formation of new clusters is assessed by light microscopy (100 × magnification). Cell culture supernatants are collected for HIV-1 p24 and HIV-2/SIVmac251 p27 core antigen measurement by ELISA. In CEMx174-infected cell cultures, which show a propensity to form syncytia induced by the virus envelope glycoproteins, syncytia are counted, in blinded fashion, by light microscopy for each well at 5 days following infection. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: Indian Rhesus macaques Dosages: 50 mg/kg or 100 mg/kg Administration: Oral administration (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	88 mg/mL (198.01 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+40% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Raltegravir (MK-0518) SDF

Molecular Weight	444.42
Formula	C₂₀H₂₁FN₆O₅
CAS No.	518048-05-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04513626	Not yet recruiting	Drug: DORAVIRINE 100 MG [Pifeltro]	HIV Infections	Centre de Recherches et d''Etude sur la Pathologie Tropicale et le Sida	September 15 2020	Phase 2
NCT03667547	Completed	Drug: Raltegravir	Human Immunodeficiency Virus (HIV) Infection	Merck Sharp & Dohme Corp.	September 27 2018	Phase 4
NCT03174977	Recruiting	Drug: 18F-Raltegravir	HIV-1-infection	University of California San Francisco\|Merck Sharp & Dohme Corp.	April 1 2018	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Integrase Signaling Pathway Map

Related Integrase Products

Cabotegravir (GSK1265744) ^New

Cabotegravir (GSK744, GSK1265744, S/GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.
Tenofovir Alafenamide (GS-7340) ^New

Tenofovir Alafenamide (GS-7340) is a prodrug of tenofovir, which is a reverse transcriptase inhibitor, used to treat HIV and Hepatitis B.
Elvitegravir (JTK-303)

Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively.
BMS-707035

BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. Phase 2.
Dolutegravir (GSK1349572)

Dolutegravir (GSK1349572, S/GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Features:A next-generation and two-metal-binding HIV integrase strand transfer inhibitor.
MK-2048

MK-2048 is a potent inhibitor of integrase (IN) and IN_R263K with IC50 of 2.6 nM and 1.5 nM, respectively.
Maraviroc

Maraviroc (UK-427857) is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.
Tenofovir Disoproxil Fumarate

Tenofovir Disoproxil Fumarate (GS-1278, Tenofovir DF) belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination.
Zidovudine

Zidovudine (ZDV, Azidothymidine, NSC 602670) is a nucleoside analogue reverse transcriptase inhibitor, used to treat HIV. It could decrease the HDR efficiency and decrease CRISPR-mediated sequence-specific genome knockin events while increaseing knockout efficiency.

Choose Your Country or Region

By Signaling Pathways

By product type

Raltegravir (MK-0518)